ConcertAI (an ASCO initiative)
About ConcertAI (an ASCO initiative)
ConcertAI is a leading healthcare AI company that leverages generative and predictive AI, real-world data (RWD), and clinical expertise to deliver practical intelligence for the treatment of oncology and other complex diseases. The company’s mission is to accelerate insights and outcomes for patients by providing research-ready data, AI technologies, and scientific expertise. They partner with biomedical innovators, healthcare providers, and medical societies to achieve this goal.
For physicians, ConcertAI offers solutions designed to enhance various aspects of patient care and clinical research, particularly within oncology. Through initiatives like CancerLinQ, which ConcertAI acquired from ASCO in December 2023, they provide oncology providers with ASCO-aligned quality solutions and analytic services. Their SmartLinQ™ application, for example, integrates ASCO Guidelines and can provide guideline-concordant care recommendations for individual patients, helping oncologists consider a complete set of treatment options. Additionally, ConcertAI’s platforms aim to simplify and accelerate clinical trial participation, reduce administrative burdens, and improve patient matching to complex clinical trial enrollment criteria through intelligent screening features like TriaLinQ™. They also offer advanced radiological image visualizations and clinical AI decision augmentation solutions for MRI and CT through TeraRecon.
Focus Areas
Business Intelligence
| Key Investors | Sixth Street, Declaration Partners, Maverick Ventures, AllianceBernstein, SymphonyAI, Baptist Health |
| Partnerships | ASCO, NVIDIA, NeoGenomics, Exigent Research, Guardant Health, Foundation Medicine, Bristol Myers Squibb, Janssen |
| Acquisitions | CancerLinQ, TeraRecon |
| Technology | CARAai™ platform (predictive and generative AI), cloud-native, AI operating system, multi-modal data integration |
What Physicians Need to Know
For physicians, ConcertAI's solutions, particularly through the CancerLinQ initiative and SmartLinQ platform, offer automated, ASCO Guideline-concordant care recommendations directly within existing EMR workflows (e.g., Epic). This can streamline decision-making and ensure adherence to the latest standards. The AI-powered clinical trial screening (TriaLinQ) can significantly reduce the burden on clinical trial staff, allowing for faster identification of eligible patients and potentially increasing patient access to trials. Furthermore, the TeraRecon Oncology Suite provides advanced AI-powered diagnostic tools to assist in screening, diagnosis, and treatment planning across the cancer care pathway. The focus on real-world data and AI aims to provide more informed care strategies and improve patient outcomes.
ConcertAI's SmartLinQ solutions work directly within the workflows of Epic and other EMRs. They also offer an open AI framework within their CARA AI platform, allowing scientists to embed and orchestrate third-party, first-party, or open-source AI algorithms. Collaborations with partners like NVIDIA further enhance their capabilities for large-scale AI applications and multi-modal data processing.
What the Web Says
ConcertAI, including its CancerLinQ initiative, is generally viewed as a leader in leveraging AI and real-world data to improve oncology care and accelerate clinical research. The company's platforms, such as RWD360 and CARA AI, are designed to provide comprehensive clinical data, enhance trial efficiency, and offer insights for treatment decisions. While product reviews highlight the innovative use of AI and data, employer reviews present a mixed picture regarding work-life balance and management.
Overall: MixedStrengths
- Accelerates clinical trial screening and patient matching with AI, significantly reducing manual effort and time.
- Provides comprehensive real-world data (RWD) platforms (RWD360, Patient360) for in-depth analysis of patient journeys and treatment patterns.
- Utilizes AI and machine learning to standardize and harmonize clinical data, including unstructured data from EHRs.
- Offers tools for tracking quality of care, evaluating quality metrics, and supporting evidence-based treatment decisions.
- Mission-driven company focused on improving patient outcomes in oncology.
- Good compensation and interesting work with medical data for some roles.
Limitations
- Mixed reviews on work-life balance, with some employees reporting long hours.
- Concerns about job security and advancement opportunities.
- Some employees report issues with management and internal politics.
- Data science teams may not always utilize machine learning as described in job descriptions.
- Limited public product reviews on platforms like G2 and Capterra specifically for ConcertAI's core offerings, making it difficult to gauge widespread user satisfaction.
- Lack of openings for new graduates in some areas.
Based on reviews from: Elion Health, Indeed, Great Place To Worku00ae, G2, ASCO Daily News, PMC, HealthTech HotSpot, ASCO Connection, Reddit, PR Newswire, Capterra
Last updated: 2026-07-01
Videos
News, demos, and interviews about ConcertAI (an ASCO initiative).
Videos load interactively. If none appear, search YouTube for ConcertAI (an ASCO initiative) →
Press & Coverage
Frequently Asked Questions
Comparisons
Related Companies
CAIMed, the Lower Saxony Center for Artificial Intelligence and Causal Methods in Medicine, is a research institution dedicated to advancing personalized healthcare through innovative AI and causal methodologies. The center aims to address widespread diseases such as cancer, cardiovascular diseases, and infections by linking research data, clinical data, and patient care data. This integrated approach, […]
Autoderm is a health technology company that provides a CE-marked AI dermatology screening API designed to analyze smartphone photos for various skin conditions. The company’s AI models are trained on a proprietary database of amateur smartphone images of skin diseases and are accessible via an API that can be integrated into various platforms, including electronic […]
OCTA is an AI-powered finance automation platform that aims to streamline financial operations and accelerate cash flow for businesses, particularly SMEs and enterprises in the Middle East, with a strong presence in the UAE and Saudi Arabia. The platform utilizes AI agents to automate tasks across the entire contract-to-cash cycle, including contract creation, e-signing, invoicing, […]
Skin Analytics is a British health technology company dedicated to the early and accurate diagnosis of skin cancer, aiming to reduce mortality from the disease. They achieve this through their flagship product, DERM, an AI-powered medical device. DERM is designed to provide dermatologist-quality skin cancer assessments, making them more accessible and reducing the burden on […]
MedTalk AI is an Australian-based healthcare AI company focused on streamlining clinical documentation for physicians and other healthcare professionals. The company’s flagship product is an ambient AI medical scribe that listens to real clinical conversations and converts them into structured, accurate notes in real-time. This technology aims to free clinicians from the burden of manual […]
allergoSMART is a healthcare AI company that offers the world’s first AI-based complete solution for personalized mite allergen avoidance. The company’s system, allergoSMART, provides a unique AI digital solution for individuals with dust mite allergies, combining targeted prevention and treatment through comprehensive home environment optimization. [3] It integrates symptom tracking, telemedicine, and air purification into […]